Ginkgo Bioworks Holdings (DNA)

As of 30 September 2026, short interest in DNA is 7,315,221 shares, up 450,204 shares over the last month. Over the last 48 readings it ranged from 4,524,898 shares (15 May 2026) to 13,339,269 shares (15 April 2025). At the reported average volume of 2.7M shares a day that is 2.7 days to cover.

<iframe src="https://xoomar.com/embed/stocks/dna" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 9 October 2026, the short share of DNA volume is 53.6%, down 9.3 points over the last five sessions. Over the last 30 readings it ranged from 37.4% (22 September 2026) to 75.2% (8 September 2026). The latest reading is 5.9 points below the 30-session average of 59.5%, on 2.1M shares reported.

As of 11 September 2026, the fails-to-deliver balance in DNA is 204 shares, up 199 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (23 July 2026) to 75,387 shares (17 April 2026). The latest reading sits at the bottom of that range.

Insiders at DNA reported 4 open-market sells worth $80K in the last 90 days and no open-market buys. Latest filing: Coen Steven P. (See remarks) on 2026-10-05.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

29 Form 144 notices on file for DNA worth $3.2M at the prices reported; 6 in the last 90 days worth $110K. Latest: Coen Steven P. filed on 2026-10-05 to sell 2,403 shares ($36K) from 2026-10-05.

10 holders report 5% or more of DNA in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 7.7% of the class (4,122,510 shares), filed 2026-07-30 for an event on 2026-06-30.

7 of the 30 tracked managers held DNA at their latest 13F, $56.7M in total at quarter-end prices. Viking Global Investors is the largest at $35.4M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 1 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 FY 2026 (quarter ended 2026-06-30) Ginkgo Bioworks Holdings reported revenue of $20.2M, down 48.5% from the same quarter a year earlier, and net loss of $46.7M (-0.75 diluted EPS). In FY 2025 it generated -$171.1M of operating cash flow.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30.